4-甲氧基-2-(2-甲基-2-丙基)嘧啶 | 140201-04-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-甲氧基-2-(2-甲基-2-丙基)嘧啶
• 英文名称: 2-t-butyl-4-methoxypyrimidine
• 英文别名: 2-(Tert-butyl)-4-methoxypyrimidine；2-tert-butyl-4-methoxypyrimidine
• CAS: 140201-04-3
• 化学式: C₉H₁₄N₂O
• 分子量: 166.223
• InChiKey: GYXLBTAQOUCOCP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  甲醇 、 4-氯-2-叔丁基嘧啶 在 sodium 作用下， 反应 12.0h， 以94%的产率得到4-甲氧基-2-(2-甲基-2-丙基)嘧啶
  参考文献：
  名称：

  Methylation of Some Deprotonated Sterically Hindered Pyrimidin-4-ols

  摘要：

  用碘甲烷将 t-丁基取代的嘧啶-4-醇中的阴离子甲基化。通过质子耦合 13C n.m.r.确定了甲基化的位点，并通过 1H n.m.r.确定了异构体的相对比例。环氮正交的叔丁基取代基明显降低了该氮的甲基化倾向，以至于观察到在这些条件下不常见的 O-甲基化。

  DOI：

  10.1071/ch9920463

文献信息

• Novel 2-Amino-4,5,6,8-Tetrahydropyrazolo[3,4-b]Thiazolo [4,5-d]Azepine Derivatives and Their Use as Allosteric Modulators of Metabotropic Glutamate Receptors
  申请人：Addex Pharma S.A.

  公开号：US20140349994A1

  公开（公告）日：2014-11-27

  The present invention relates to novel compounds of Formula (I), wherein M and R 1 are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR 4 ”) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR 4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR 4 is involved.

  本发明涉及式（I）的新化合物，其中M和R1如式（I）中所定义；该发明化合物是代谢型谷氨酸受体亚型4（“mGluR4”）的调节剂，对于治疗或预防中枢神经系统疾病以及其他受mGluR4受体调节的疾病具有用处。该发明还涉及制药组合物以及利用这类化合物制造药物的用途，以及利用这类化合物预防和治疗涉及mGluR4的疾病的用途。
• FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
  申请人：Gilead Sciences, Inc.

  公开号：US20150175560A1

  公开（公告）日：2015-06-25

  The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein X, Y, Z, R 2 , R 3 , R 4 , p and q are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及一类钠通道抑制剂化合物及其在治疗各种疾病状态中的应用，包括心血管疾病和糖尿病。具体实施例中，该化合物的结构由式I给出：其中X、Y、Z、R2、R3、R4、p和q如本文所述，以及制备和使用该化合物的方法以及含有该化合物的药物组合物。
• Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression
  申请人：Bursavich Matthew Gregory

  公开号：US20090325964A1

  公开（公告）日：2009-12-31

  The present teachings relate to piperazine metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators having Formula I: wherein the constituent variables are as defined herein. The present teachings further relate to methods for the preparation of the compounds, and to methods for using the compounds for treatment of diseases and disorders including schizophrenia, paranoia, depression, manic-depressive illness and anxiety.

  本发明涉及具有公式I的哌嗪代谢型谷氨酸受体5（mGluR5）负向变构调节剂： 其中，组成变量如本文所定义。本发明还涉及制备该化合物的方法，并涉及使用该化合物治疗疾病和障碍的方法，包括精神分裂症、偏执症、抑郁症、躁郁病和焦虑症。
• Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands
  申请人：Cook, II James H.

  公开号：US20100099684A1

  公开（公告）日：2010-04-22

  The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

  本公开提供公式I的化合物，包括其盐，以及使用这些化合物的组合物和方法。这些化合物是尼古丁α7受体的配体，可能对中枢神经系统的各种疾病，特别是情感和神经退行性疾病的治疗有用。
• Antibacterial Compositions
  申请人：Haydon David John

  公开号：US20110263590A1

  公开（公告）日：2011-10-27

  Compounds of formula (I) have antibacterial activity: wherein: m is 0 or 1; Q is hydrogen or cyclopropyl; Alk is an optionally substituted, divalent C 1 -C 6 alkylene, alkenylene or alkynylene radical which may contain an ether (—O—), thioether (—S—) or amino (—NR)— link, wherein R is hydrogen, —CN or C 1 -C 3 alkyl; X is —C(═O)NR 6 —, —S(O)NR 6 —, —C(═O)O— or —S(═O)O— wherein R 6 is hydrogen, optionally substituted C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, -Cyc, or —(C 1 -C 3 alkyl)-Cyc wherein Cyc is optionally substituted monocyclic carbocyclic or heterocyclic having 3-7 ring atoms; Z is N or CH, or CF; R 2 and R 3 are as defined in the description.

  式(I)的化合物具有抗菌活性：其中：m为0或1；Q为氢或环丙基；Alk为可选取代的二价C1-C6烷基、烯基或炔基基团，其中可以含有醚（—O—）、硫醚（—S—）或氨基（—NR）键，其中R为氢、—CN或C1-C3烷基；X为—C（═O）NR6—、—S（O）NR6—、—C（═O）O—或—S（═O）O—，其中R6为氢、可选取代的C1-C6烷基、C2-C6烯基、C2-C6炔基、-Cyc或—（C1-C3烷基）-Cyc，其中Cyc为可选取代的具有3-7个环原子的单环碳环或杂环；Z为N或CH，或CF；R2和R3如描述中所定义。